Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
NCT: NCT06710223 · RECRUITING
Brief Summary
The goal of this Phase 1b clinical trial is to evaluate the safety and efficacy of cryoablation and hepatic arterial administration of SD-101 in participants with advanced hepatocellular carcinoma. After this procedure, participants will be treated with tremelimumab and durvalumab every 4 weeks (STRIDE regimen).
Frequently Asked Questions
What is Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab?
Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab is a clinical trial registered under NCT06710223. Current status: RECRUITING.
What is the status of NCT06710223?
The current status of NCT06710223 (Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab) is: RECRUITING.
When did Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab start?
Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab started on 2025-01-03.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.